Suppr超能文献

微型T细胞受体:用于从诱导多能干细胞生成T细胞的截短型T细胞受体。

Mini-TCRs: Truncated T cell receptors to generate T cells from induced pluripotent stem cells.

作者信息

Takayanagi Shin-Ichiro, Wang Bo, Hasegawa Saki, Nishikawa Satoshi, Fukumoto Ken, Nakano Kohei, Chuganji Sayaka, Kato Yuya, Kamibayashi Sanae, Minagawa Atsutaka, Kunisato Atsushi, Nozawa Hajime, Kaneko Shin

机构信息

Kirin Central Research Institute, Kirin Holdings Company, Ltd., 26-1, Muraoka-Higashi 2, Fujisawa-shi, Kanagawa 251-8555, Japan.

Shin Kaneko Laboratory, Department of Cell Growth and Differentiation, Center for iPS Cell Research and Application (CiRA), Kyoto University, 53 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto 606-8507, Japan.

出版信息

Mol Ther Methods Clin Dev. 2023 Sep 16;31:101109. doi: 10.1016/j.omtm.2023.101109. eCollection 2023 Dec 14.

Abstract

Allogeneic T cell platforms utilizing induced pluripotent stem cell (iPSC) technology exhibit significant promise for the facilitation of adoptive immunotherapies. While mature T cell receptor (TCR) signaling plays a crucial role in generating T cells from iPSCs, the introduction of exogenous mature TCR genes carries a potential risk of causing graft-versus-host disease (GvHD). In this study, we present the development of truncated TCRα and TCRβ chains, termed mini-TCRs, which lack variable domains responsible for recognizing human leukocyte antigen (HLA)-peptide complexes. We successfully induced cytotoxic T lymphocytes (CTLs) from iPSCs by employing mini-TCRs. Combinations of TCRα and TCRβ fragments were screened from mini-TCR libraries based on the surface localization of CD3 proteins and their ability to transduce T cell signaling. Consequently, mini-TCR-expressing iPSCs underwent physiological T cell development, progressing from the CD4 and CD8 double-positive stage to the CD8 single-positive stage. The resulting iPSC-derived CTLs exhibited comparable cytokine production and cytotoxicity in comparison to that of full-length TCR-expressing T lymphocytes when chimeric antigen receptors (CARs) were expressed. These findings demonstrate the potential of mini-TCR-carrying iPSCs as a versatile platform for CAR T cell therapy, offering a promising avenue for advancing adoptive immunotherapies.

摘要

利用诱导多能干细胞(iPSC)技术的同种异体T细胞平台在促进过继性免疫疗法方面显示出巨大潜力。虽然成熟的T细胞受体(TCR)信号传导在从iPSC产生T细胞的过程中起着关键作用,但引入外源性成熟TCR基因存在引发移植物抗宿主病(GvHD)的潜在风险。在本研究中,我们展示了截短的TCRα和TCRβ链(称为微型TCR)的开发,它们缺乏负责识别人类白细胞抗原(HLA)-肽复合物的可变结构域。我们通过使用微型TCR成功地从iPSC诱导出细胞毒性T淋巴细胞(CTL)。基于CD3蛋白的表面定位及其转导T细胞信号的能力,从微型TCR文库中筛选TCRα和TCRβ片段的组合。因此,表达微型TCR的iPSC经历了生理性T细胞发育,从CD4和CD8双阳性阶段发展到CD8单阳性阶段。当表达嵌合抗原受体(CAR)时,所得的iPSC来源的CTL与表达全长TCR的T淋巴细胞相比,表现出相当的细胞因子产生和细胞毒性。这些发现证明了携带微型TCR的iPSC作为CAR T细胞疗法通用平台的潜力,为推进过继性免疫疗法提供了一条有前景的途径。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9c34/10562677/ebe1e12a6b15/fx1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验